Targeting the Cardiotoxicity of Epidermal Growth Factor Receptor Inhibitors∗ by Dipesh Uprety, MBBS, Aaron S. Mansfield, MD

Get full text

The Role of Osimertinib in Treatment Naïve Epidermal Growth Factor Receptor–Mutated Stage IIIB or IV Non–Small-Cell Lung Cancer Patients by Dipesh Uprety, Amir Bista, Yazhini Vallatharasu, Lubina Arjyal

Get full text

A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms by Joel Rivera-Concepcion, Ying-Chun Lo, Dipesh Uprety, Alex A. Adjei, Vinicius Ernani, Konstantinos Leventakos

Get full text

529 Impact of histology and PD-L1 status on immune checkpoint inhibitors in the treatment of non-small cell lung cancer by Seongho Kim, Tarik Hadid, Hirva Mamdani, Khalil Choucair, Hyejong Jang, Shadia I Jalal, Dipesh Uprety

A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors by Gary Edward Richardson, Raed Al-Rajabi, Dipesh Uprety, Anis Hamid, Stephen K. Williamson, Joaquina Baranda, Hirva Mamdani, Ya-Li Lee, Nitika, Li Li, Xingli Wang, Xunwei Dong

Get full text

Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing by So Yeon Kim, MD, Jun Yin, MD, Stephen Bohlman, MD, PhD, Phillip Walker, PhD, Sanja Dacic, MD, PhD, Chul Kim, MD, Hina Khan, MD, Stephen V. Liu, MD, Patrick C. Ma, MD, Misako Nagasaka, MD, PhD, Karen L. Reckamp, MD, Jim Abraham, PhD, Dipesh Uprety, MD, Feng Wang, PhD, Joanne Xiu, PhD, Jian Zhang, PhD, Haiying Cheng, MD, PhD, Balazs Halmos, MD

Get full text